Apostrophe has been acquired by Hims & Hers Health, Inc.
The private shareholders of Apostrophe have sold the company to Hims & Hers Health, Inc.
Founded in 2012 and based in Oakland, California, Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized skincare brand and visionary leadership team, the company has experienced rapid growth over the past several years.
Based in San Francisco, California, Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.
Oaklins’ team in Los Angeles acted as advisor to the private shareholders of Apostrophe in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Michael Garcia
Oaklins Intrepid
Hayden Rosenthal
Oaklins Intrepid
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn morePiper PE and Cool Japan Fund have backed a management buy-out of Inside Travel Group
Inside Travel Group (ITG) has been sold to Piper PE and Cool Japan Fund. This acquisition aligns with ITG’s goal of becoming the leading specialist in tailor-made and group tours across Asia. Piper PE and Cool Japan Fund will continue to support ITG’s founders and management team, driving the business’ growth in Japan and other Asian destinations.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more